20 completed, 12 terminated, 9 active not recruiting, 5 withdrawn. 46 Phase 1, 17 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 46 | Completed 20, Terminated 12, Active not recruiting 9, Withdrawn 5 |
| Phase 2 | 17 | Active not recruiting 5, Completed 5, Terminated 4, Withdrawn 3 |
Follow copanlisib: new trials by email Literature Review of copanlisib trials Research Report on copanlisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer copanlisib, Avelumab - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2025-06-02 | 2025-06-15 | |
| A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer Copanlisib, Degarelix, Radical Prostatectomy - Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2024-01-11 | 2024-10-31 | |
| Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Copanlisib Hydrochloride, Venetoclax - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 8 | 2022-06-29 | 2026-04-20 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Rituximab, Etoposide, Copanlisib - Burkitt Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2022-03-24 | 2024-07-09 |
| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors Copanlisib, Elimusertib - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-22 | 2022-05-27 | |
| Copanlisib Plus Venetoclax in R/R DLBCL Copanlisib, Venetoclax - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 48 | 2021-09-08 | 2026-01-07 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Copanlisib, Pertuzumab, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2021-05-20 | 2025-10-01 |
| Lung Cancer With Copanlisib and Durvalumab Durvalumab, Copanlisib - Non Small Cell Lung Cancer | Phase 1 | Completed | Zhonglin Hao | 11 | 2021-05-12 | 2025-11-18 |
| Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2021-03-01 | 2026-07-31 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2020-07-17 | 2026-10-27 |
| Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib - Thyroid Carcinoma, Thyroid Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 8 | 2020-06-26 | 2025-09-08 |
| Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer Abemaciclib, Biopsy Procedure, Biospecimen Collection - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2020-06-17 | 2026-09-08 |
| Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma Copanlisib, Nivolumab, Rituximab - Indolent Lymphoma | Phase 1 | Terminated | University of Michigan Rogel Cancer Center | 6 | 2020-06-15 | 2024-09-27 |
| A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Rucaparib, Copanlisib - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | Brown University | 13 | 2020-04-03 | 2025-05-04 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma Copanlisib, Gemcitabine, Carboplatin - Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | University of Washington | 12 | 2020-03-31 | 2023-06-29 |
| Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma Copanlisib, Romidepsin - Lymphoma, T-Cell | Phase 1 | Withdrawn | Columbia University | 2020-02-01 | 2020-08-13 | |
| Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 39 | 2019-11-21 | 2026-09-29 |
| Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer Copanlisib, Trastuzumab emtansine - HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 1 | Terminated | Cancer Trials Ireland | 2 | 2019-11-12 | 2025-07-22 |
| Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. Copanlisib, Venetoclax - Non-Hodgkin Lymphoma | Phase 1 | Terminated | Swiss Cancer Institute | 7 | 2019-11-04 | 2022-04-01 |
Showing 20 of 46. Sign in to see all of them.
Lymphoma, Non-Hodgkin (9) · Neoplasm Metastasis (8) · Breast Neoplasms (7) · Lymphoma, Large B-Cell, Diffuse (4) · Neoplasms (4) · Hodgkin Disease (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Carcinoma, Non-Small-Cell Lung (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, T-Cell, Peripheral (2) · Prostatic Neoplasms (2) · Recurrence (2)
Bayer (13) · National Cancer Institute (NCI) (8) · Memorial Sloan Kettering Cancer Center (4) · Cancer Trials Ireland (2) · City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · Brown University (1) · Chonnam National University Hospital (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · Fox Chase Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (33) · Canada (3) · Germany (3) · Belgium (2) · France (2) · Ireland (2) · Netherlands (2) · South Korea (2) · Spain (2) · China (1) · Japan (1) · Romania (1) · Singapore (1) · Switzerland (1) · United Kingdom (1)
Timothy A Yap (2) · A P Chen (1) · Alan L Ho, MD, PhD (1) · Alexey Danilov (1) · Alexey V Danilov (1) · Anastasios Stathis, MD (1) · Benedito Carneiro, MD, MS (1) · Changchun Deng, MD, PhD (1) · Chong-Xian Pan, MD PhD (1) · Christian Grommes, MD (1) · Connie Batlevi, MD, PhD (1) · Cynthia X Ma (1) · Dana Rathkopf, MD (1)
PMID 27672108, PMID 31029646, PMID 31619463, PMID 32314268, PMID 32379297, PMID 34322775, PMID 35322287, PMID 37171634, PMID 39863139, PMID 41528970, PMID 42493490, PMID 5035790
UM1CA186688 (3), UM1CA186704 (3), P30CA033572 (2), UM1CA186689 (2), 2015 (1), 2016 (1), 2017 (1), 2018 (1), ZIABC011078 (1)